Pharmaceutical compositions for treating ebola virus disease
OwnerSusan Eve Vecht-Lifshitzinventor
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds and pharmaceutical compositions adapted to reduce a load of an RNA virus by at least 50%, the virus causing a pathogenic disease in a mammalian subject, the compound adapted to inhibit the formation of S-adenosyl methionine (SAM) in the virus, the compound being a DOTIL inhibitor, wherein the compound has a molecular weight of less than 1000, and a therapeutic index (TI=LD.sub.50:ED.sub.50) greater than 30 in the mammalian subject.
Claims9
A method for reducing a load of an infectious RNA virus causing a hemorrhagic pathogenic disease in a mammalian subject, the method comprising administering to said subject a DOT1L inhibitor compound, said compound adapted to reduce a load of said RNA virus by at least 50% in said mammalian subject, wherein said compound has a therapeutic index (TI=LD50:ED50) greater than 30 in said mammalian subject against said infectious RNA virus, wherein said infectious RNA virus is Ebola virus.
Dependencies are inferred from the claim text.